GSK is experiencing growth amidst challenges, with a 13% sales increase and R&D innovations. However, facing declining U.S. vaccine sales and legal issues, GSK must manage risks carefully. Strategic opportunities like new vaccine launches and alliances position GSK for future success, despite external threats.